Prometheus Biosciences, Inc.

RXDXNASDAQHealthcare

$199.92

+$0.18(+0.09%)

Market Cap$9.6B

P/E Ratio—

52W High$199.96

52W Low$23.27

Avg Volume1.3M

Open$199.68

Beta-0.49

Forecast Market Cap PE Ratio

Prometheus Biosciences, Inc.（RXDX）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

rxdx · 股价预测 · 11 位分析师（近3月）· FMP · 更新于 2025年9月19日

分析师评级与共识

基于过去 3 个月内 11 位华尔街分析师

Hold

11 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 11 · 买入占比: 36.4%

12 个月目标价

High

$200

Consensus

$139

-30.7% upside

Low

$67.00

Median: $142 · Last Close: $199.92

Prometheus Biosciences, Inc.（RXDX）的分析师共识为 Hold，基于过去 3 个月内 11 位华尔街分析师的评级。RXDX 的 12 个月平均目标价为 $138.57，相对当前价 $199.92 代表 -30.7% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

Historical priceConsensus $139 (-30.7%)High $200Low $67

Consensus Target

$138.57

-30.7% upside

High Target

$200

0.0%

Low Target

$67

-66.5%

Current Price

$199.92

as of today

Based on analyst price targets, the RXDX stock price prediction for the next 12 months ranges from $67 to $200. The consensus RXDX price forecast of $138.57 implies -30.7% upside from the current price of $199.92.

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-10	$199.89	↓ 0.02%	$199.68	$200.09

1-day model range: $199.68–$200.09. Peak: $200.09 (-0.02%).

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

NEUTRAL

Based on 14 technical indicators

50%43%7%

7Buy

6Neutral

1Sell

RSI (14)89.3Overbought

MACDBULLISH

Refreshes daily from EOD close

Moving Averages · RXDX · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$199.31BUY

MA 10$199.09BUY

MA 20$198.02BUY

MA 50$0.00NEUTRAL

MA 100$0.00NEUTRAL

MA 200$0.00NEUTRAL

Current $RXDX · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$199.44BUY

EMA 10$199.02BUY

EMA 20$198.07BUY

EMA 50$0.00NEUTRAL

EMA 100$0.00NEUTRAL

EMA 200$0.00NEUTRAL

Current $RXDX · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2023-05-10	RBC Capital	Maintains	Sector Perform→Perform
2023-05-10	Jefferies	Downgrade ↓	Buy→Hold
2023-04-18	RBC Capital	Downgrade ↓	Outperform→Perform
2023-04-18	Credit Suisse	Downgrade ↓	Outperform→Neutral
2023-04-18	Piper Sandler	Downgrade ↓	Overweight→Neutral
2023-04-18	Wells Fargo	Downgrade ↓	Overweight→Equal Weight
2023-04-17	Guggenheim	Downgrade ↓	Buy→Neutral
2023-04-17	Stifel	Downgrade ↓	Buy→Hold
2023-03-06	Guggenheim	Maintains	Buy→Buy
2023-03-01	Oppenheimer	Maintains	Outperform→Outperform

RBC Capital2023-05-10

Maintains

Sector Perform→Perform

Jefferies2023-05-10

Downgrade ↓

Buy→Hold

RBC Capital2023-04-18

Downgrade ↓

Outperform→Perform

Credit Suisse2023-04-18

Downgrade ↓

Outperform→Neutral

Piper Sandler2023-04-18

Downgrade ↓

Overweight→Neutral

Wells Fargo2023-04-18

Downgrade ↓

Overweight→Equal Weight

Guggenheim2023-04-17

Downgrade ↓

Buy→Neutral

Stifel2023-04-17

Downgrade ↓

Buy→Hold

Guggenheim2023-03-06

Maintains

Buy→Buy

Oppenheimer2023-03-01

Maintains

Outperform→Outperform

Wall Street analysts have recently issued updated ratings on Prometheus Biosciences, Inc. (RXDX) stock. Of the recent 43 rating actions, 1 were upgrades and 8 were downgrades. 11 analysts currently cover RXDX.

分析师推荐趋势

Buy ratings1 → 0↓ 1

Hold ratings0 → 2↑ +2

Sell ratings0 → 0

RXDX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

—

Revenue Next Year

—

EPS This Year

—

EPS Next Year

—

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast RXDX EPS of $— for the current fiscal year, based on estimates from 0 analysts. The RXDX revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

RXDX 股价预测由两类独立数据源支撑：来自 11 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。RXDX 的共识目标价为 $138.57（-30.7% 上行空间），分析师共识为 Hold。

RXDX 的短期预测（明日）为 $199.89（-0.02%）。

Prometheus Biosciences, Inc. 在 NASDAQ 上市，代码 RXDX。RXDX 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 36% 对应 Hold 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

RXDX 预测 · 8 个问题

根据 11 位华尔街分析师，RXDX 的 12 个月平均目标价为 $138.57，最高 $200.00、最低 $67.00。若有图表，中位目标价可在上方查看。相对当前价 $199.92，隐含约 -30.7% 的上行空间。

RXDX 目标价RXDX 分析师目标价RXDX 12个月目标价目标价 RXDX

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.